This report aims to provide a comprehensive presentation of the global market for CAR-T Therapy in Haematological Malignancy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR-T Therapy in Haematological Malignancy. This report contains market size and forecasts of CAR-T Therapy in Haematological Malignancy in global, including the following market information:
Global CAR-T Therapy in Haematological Malignancy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global CAR-T Therapy in Haematological Malignancy market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Allogeneic Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of CAR-T Therapy in Haematological Malignancy include Celgene (Juno Therapeutics), Novartis, Gilead (Kite Pharma), Pfizer, CARsgen Therapeutics, Autolus Therapeutics, Aurora BioPharma, Sorrento Therapeutics and Mustang Bio, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the CAR-T Therapy in Haematological Malignancy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CAR-T Therapy in Haematological Malignancy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, by Type, 2022 (%)
Allogeneic
Autologous
Global CAR-T Therapy in Haematological Malignancy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, by Application, 2022 (%)
Hospitals
Cancer Research Centers
Others
Global CAR-T Therapy in Haematological Malignancy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global CAR-T Therapy in Haematological Malignancy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CAR-T Therapy in Haematological Malignancy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies CAR-T Therapy in Haematological Malignancy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Celgene (Juno Therapeutics)
Novartis
Gilead (Kite Pharma)
Pfizer
CARsgen Therapeutics
Autolus Therapeutics
Aurora BioPharma
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Collectis
Allogene Therapeutics
Celyad
Outline of Major Chapters:
Chapter 1: Introduces the definition of CAR-T Therapy in Haematological Malignancy, market overview.
Chapter 2: Global CAR-T Therapy in Haematological Malignancy market size in revenue.
Chapter 3: Detailed analysis of CAR-T Therapy in Haematological Malignancy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CAR-T Therapy in Haematological Malignancy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 CAR-T Therapy in Haematological Malignancy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CAR-T Therapy in Haematological Malignancy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CAR-T Therapy in Haematological Malignancy Overall Market Size
2.1 Global CAR-T Therapy in Haematological Malignancy Market Size: 2022 VS 2032
2.2 Global CAR-T Therapy in Haematological Malignancy Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CAR-T Therapy in Haematological Malignancy Players in Global Market
3.2 Top Global CAR-T Therapy in Haematological Malignancy Companies Ranked by Revenue
3.3 Global CAR-T Therapy in Haematological Malignancy Revenue by Companies
3.4 Top 3 and Top 5 CAR-T Therapy in Haematological Malignancy Companies in Global Market, by Revenue in 2022
3.5 Global Companies CAR-T Therapy in Haematological Malignancy Product Type
3.6 Tier 1, Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Players in Global Market
3.6.1 List of Global Tier 1 CAR-T Therapy in Haematological Malignancy Companies
3.6.2 List of Global Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global CAR-T Therapy in Haematological Malignancy Market Size Markets, 2022 & 2032
4.1.2 Allogeneic
4.1.3 Autologous
4.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
4.2.1 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2018-2023
4.2.2 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, 2024-2032
4.2.3 By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global CAR-T Therapy in Haematological Malignancy Market Size, 2022 & 2032
5.1.2 Hospitals
5.1.3 Cancer Research Centers
5.1.4 Others
5.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
5.2.1 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2018-2023
5.2.2 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, 2024-2032
5.2.3 By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global CAR-T Therapy in Haematological Malignancy Market Size, 2022 & 2032
6.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue & Forecasts
6.2.1 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2018-2023
6.2.2 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue, 2024-2032
6.2.3 By Region - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.3.2 US CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.3.3 Canada CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.3.4 Mexico CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.4.2 Germany CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.3 France CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.4 U.K. CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.5 Italy CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.6 Russia CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.7 Nordic Countries CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.4.8 Benelux CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.5.2 China CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.3 Japan CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.4 South Korea CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.5 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.5.6 India CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.6.2 Brazil CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.6.3 Argentina CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032
6.7.2 Turkey CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7.3 Israel CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7.4 Saudi Arabia CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
6.7.5 UAE CAR-T Therapy in Haematological Malignancy Market Size, 2018-2032
7 CAR-T Therapy in Haematological Malignancy Companies Profiles
7.1 Celgene (Juno Therapeutics)
7.1.1 Celgene (Juno Therapeutics) Company Summary
7.1.2 Celgene (Juno Therapeutics) Business Overview
7.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.1.4 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.1.5 Celgene (Juno Therapeutics) Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.2.4 Novartis CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Gilead (Kite Pharma)
7.3.1 Gilead (Kite Pharma) Company Summary
7.3.2 Gilead (Kite Pharma) Business Overview
7.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.3.4 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.3.5 Gilead (Kite Pharma) Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.4.4 Pfizer CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 CARsgen Therapeutics
7.5.1 CARsgen Therapeutics Company Summary
7.5.2 CARsgen Therapeutics Business Overview
7.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.5.4 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.5.5 CARsgen Therapeutics Key News & Latest Developments
7.6 Autolus Therapeutics
7.6.1 Autolus Therapeutics Company Summary
7.6.2 Autolus Therapeutics Business Overview
7.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.6.4 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.6.5 Autolus Therapeutics Key News & Latest Developments
7.7 Aurora BioPharma
7.7.1 Aurora BioPharma Company Summary
7.7.2 Aurora BioPharma Business Overview
7.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.7.4 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.7.5 Aurora BioPharma Key News & Latest Developments
7.8 Sorrento Therapeutics
7.8.1 Sorrento Therapeutics Company Summary
7.8.2 Sorrento Therapeutics Business Overview
7.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.8.4 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.8.5 Sorrento Therapeutics Key News & Latest Developments
7.9 Mustang Bio
7.9.1 Mustang Bio Company Summary
7.9.2 Mustang Bio Business Overview
7.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.9.4 Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.9.5 Mustang Bio Key News & Latest Developments
7.10 Bluebird Bio
7.10.1 Bluebird Bio Company Summary
7.10.2 Bluebird Bio Business Overview
7.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.10.4 Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.10.5 Bluebird Bio Key News & Latest Developments
7.11 Collectis
7.11.1 Collectis Company Summary
7.11.2 Collectis Business Overview
7.11.3 Collectis CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.11.4 Collectis CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.11.5 Collectis Key News & Latest Developments
7.12 Allogene Therapeutics
7.12.1 Allogene Therapeutics Company Summary
7.12.2 Allogene Therapeutics Business Overview
7.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.12.4 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.12.5 Allogene Therapeutics Key News & Latest Developments
7.13 Celyad
7.13.1 Celyad Company Summary
7.13.2 Celyad Business Overview
7.13.3 Celyad CAR-T Therapy in Haematological Malignancy Major Product Offerings
7.13.4 Celyad CAR-T Therapy in Haematological Malignancy Revenue in Global Market (2018-2023)
7.13.5 Celyad Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. CAR-T Therapy in Haematological Malignancy Market Opportunities & Trends in Global Market
Table 2. CAR-T Therapy in Haematological Malignancy Market Drivers in Global Market
Table 3. CAR-T Therapy in Haematological Malignancy Market Restraints in Global Market
Table 4. Key Players of CAR-T Therapy in Haematological Malignancy in Global Market
Table 5. Top CAR-T Therapy in Haematological Malignancy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global CAR-T Therapy in Haematological Malignancy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global CAR-T Therapy in Haematological Malignancy Revenue Share by Companies, 2018-2023
Table 8. Global Companies CAR-T Therapy in Haematological Malignancy Product Type
Table 9. List of Global Tier 1 CAR-T Therapy in Haematological Malignancy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CAR-T Therapy in Haematological Malignancy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - CAR-T Therapy in Haematological Malignancy Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2024-2032
Table 30. Celgene (Juno Therapeutics) Company Summary
Table 31. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Product Offerings
Table 32. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 33. Celgene (Juno Therapeutics) Key News & Latest Developments
Table 34. Novartis Company Summary
Table 35. Novartis CAR-T Therapy in Haematological Malignancy Product Offerings
Table 36. Novartis CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 37. Novartis Key News & Latest Developments
Table 38. Gilead (Kite Pharma) Company Summary
Table 39. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Product Offerings
Table 40. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 41. Gilead (Kite Pharma) Key News & Latest Developments
Table 42. Pfizer Company Summary
Table 43. Pfizer CAR-T Therapy in Haematological Malignancy Product Offerings
Table 44. Pfizer CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Key News & Latest Developments
Table 46. CARsgen Therapeutics Company Summary
Table 47. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 48. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 49. CARsgen Therapeutics Key News & Latest Developments
Table 50. Autolus Therapeutics Company Summary
Table 51. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 52. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 53. Autolus Therapeutics Key News & Latest Developments
Table 54. Aurora BioPharma Company Summary
Table 55. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Product Offerings
Table 56. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 57. Aurora BioPharma Key News & Latest Developments
Table 58. Sorrento Therapeutics Company Summary
Table 59. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 60. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 61. Sorrento Therapeutics Key News & Latest Developments
Table 62. Mustang Bio Company Summary
Table 63. Mustang Bio CAR-T Therapy in Haematological Malignancy Product Offerings
Table 64. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 65. Mustang Bio Key News & Latest Developments
Table 66. Bluebird Bio Company Summary
Table 67. Bluebird Bio CAR-T Therapy in Haematological Malignancy Product Offerings
Table 68. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 69. Bluebird Bio Key News & Latest Developments
Table 70. Collectis Company Summary
Table 71. Collectis CAR-T Therapy in Haematological Malignancy Product Offerings
Table 72. Collectis CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 73. Collectis Key News & Latest Developments
Table 74. Allogene Therapeutics Company Summary
Table 75. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Product Offerings
Table 76. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 77. Allogene Therapeutics Key News & Latest Developments
Table 78. Celyad Company Summary
Table 79. Celyad CAR-T Therapy in Haematological Malignancy Product Offerings
Table 80. Celyad CAR-T Therapy in Haematological Malignancy Revenue (US$, Mn) & (2018-2023)
Table 81. Celyad Key News & Latest Developments
List of Figures
Figure 1. CAR-T Therapy in Haematological Malignancy Segment by Type in 2022
Figure 2. CAR-T Therapy in Haematological Malignancy Segment by Application in 2022
Figure 3. Global CAR-T Therapy in Haematological Malignancy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global CAR-T Therapy in Haematological Malignancy Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global CAR-T Therapy in Haematological Malignancy Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CAR-T Therapy in Haematological Malignancy Revenue in 2022
Figure 8. By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 9. By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 10. By Type - Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 12. By Application - Global CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 14. By Region - Global CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 15. By Country - North America CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 16. US CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 17. Canada CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 20. Germany CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 21. France CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 23. Italy CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 24. Russia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 28. China CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 29. Japan CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 32. India CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 34. Brazil CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa CAR-T Therapy in Haematological Malignancy Revenue Market Share, 2018-2032
Figure 37. Turkey CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 38. Israel CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 40. UAE CAR-T Therapy in Haematological Malignancy Revenue, (US$, Mn), 2018-2032
Figure 41. Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Novartis CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Aurora BioPharma CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Mustang Bio CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Bluebird Bio CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Collectis CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Celyad CAR-T Therapy in Haematological Malignancy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
